$Caribou Biosciences (CRBU.US)$ Positive Cash runway extende...
Positive
Cash runway extended into H2 2027 with $183.9M in cash and equivalents
CB-010 showing potential outcomes comparable to approved autologous CAR-T therapies
Completed enrollment in both CB-010 and CB-011 clinical trials
R&D expenses decreased by 22% YoY to $27.7M due to strategic prioritization
Negative
Net loss increased to $54.1M from $37.7M YoY
Licensing revenue declined to $2.7M from $3.5M YoY
$21.3M in non-recurring impairment charges from pipeline prioritization
Workforce reduction implemented as part of strategic prioritization
Cash runway extended into H2 2027 with $183.9M in cash and equivalents
CB-010 showing potential outcomes comparable to approved autologous CAR-T therapies
Completed enrollment in both CB-010 and CB-011 clinical trials
R&D expenses decreased by 22% YoY to $27.7M due to strategic prioritization
Negative
Net loss increased to $54.1M from $37.7M YoY
Licensing revenue declined to $2.7M from $3.5M YoY
$21.3M in non-recurring impairment charges from pipeline prioritization
Workforce reduction implemented as part of strategic prioritization
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Market Insights
Hot Topics Hot Topics
Trump's 'Taco deal' sparks market rebound : Market rebound sustainable ?
1. If tariffs pause, which sectors benefit first? 2. Trump's "threat-compromise" cycle normalizes—how to hedge across assets?
Moo Options Explorer
Apr 7 17:28
Weekly roundup: Tariff turmoil and recession fears dominate
Moo Options Explorer
Mar 31 17:01
Weekly roundup: Tariff concerns and Tesla’s rollercoaster ride